Moderna, Inc.’s revenues from its COVID-19 vaccines have begun an anticipated decline, reflecting the broader trend in drugs and vaccines for SARS-CoV-2 as the pandemic begins to wind down, and it is forecasting a steep drop in coronavirus vaccine sales in 2023. But the messenger RNA-focused biotech’s fourth quarter and full year 2022 earnings also hint that the post-pandemic future that it has been building toward is taking shape as newer mRNA-based products inch closer to the market, particularly in infectious diseases like respiratory syncytial virus (RSV) and oncology.
With COVID Crash In Sight, Moderna’s Post-Pandemic Future Starts To Take Shape
The company reported a fourth quarter decline in SARS-CoV-2 vaccine sales and guided for sales of $5bn in 2023. It is looking ahead to filing for approval of its RSV vaccine.
More from Earnings
• By
As drugmakers update investors on first quarter financial performance, uncertainty around global trade and US regulatory oversight is likely to dominate discussions.
• By
Sector-specific tariffs, including on pharmaceuticals, could be announced as early as this week.
• By
Industry lobbied for pharmaceuticals to be exempt from Trump’s sweeping US tariffs and the effort appears to have paid off. J&J, Lilly and Merck & Co. even got shout outs.
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
More from Business
• By
Chinese biopharma companies’ alliance strategies are transitioning from immediate cash needs to more strategic management of portfolios, as MNCs continue to hunt for derisked assets.
• By
As drugmakers update investors on first quarter financial performance, uncertainty around global trade and US regulatory oversight is likely to dominate discussions.
• By
Faced with Trump’s hostile tariff moves, the UK aims to speed up clinical trial start times to support its pharma sector and invest £600m in a new health data research service.